CD207 CAR-T cells Therapy(Beijing Friendship Hospital)

N/A

Report date: 2022/08/01 10:26:40

Base Information

Drug NameCD207 CAR-T cells Therapy(Beijing Friendship Hospital)
Drug Alias NameCD207 CAR-T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsC-type lectin domain family 4 member K modulators
TargetsC-type lectin domain family 4 member K
Therapy Area/IndicationsHistiocytosis, Langerhans-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Friendship Hospital Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Friendship Hospital Co Ltd
Inactive CompaniesN/A
Active IndicationsHistiocytosis, Langerhans-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A